ProShare Advisors
BHVN

ProShare Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

ProShare Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,975
Closed -$1.21M – 1921
2022
Q3 		$1.21M Sell
7,975
-58
-0.7% -$8.6K ﹤0.01% 704
2022
Q2 		$1.17M Sell
8,033
-3,816
-32% -$487K ﹤0.01% 731
2022
Q1 		$1.41M Sell
11,849
-1,764
-13% -$220K ﹤0.01% 804
2021
Q4 		$1.88M Buy
13,613
+5,105
+60% +$649K ﹤0.01% 781
2021
Q3 		$1.18M Sell
8,508
-5,509
-39% -$688K ﹤0.01% 846
2021
Q2 		$1.36M Buy
14,017
+1,159
+9% +$94.1K ﹤0.01% 865
2021
Q1 		$879K Buy
12,858
+2,198
+21% +$178K ﹤0.01% 1069
2020
Q4 		$914K Buy
10,660
+4,763
+81% +$404K ﹤0.01% 925
2020
Q3 		$383K Sell
5,897
-516
-8% -$33.8K ﹤0.01% 1048
2020
Q2 		$469K Buy
+6,413
New +$341K ﹤0.01% 979
2020
Q1 		– Sell
-5,302
Closed -$289K – 1790
2019
Q4 		$289K Buy
+5,302
New +$263K ﹤0.01% 1356

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

ProShare Advisors's BHVN Position: Q4 2022 in Review

ProShare Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 7,975 shares — an estimated $1.21M sold.

ProShare Advisors first reported a position in BHVN in Q4 2019 and held it in 11 quarters. The position peaked at $1.88M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • ProShare Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • ProShare Advisors sold 7,975 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.21M.
  • ProShare Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 11 quarters.
  • ProShare Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.88M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.